Leuprorelin: Subcutaneous Depot Formulation (Eligard®) for Advanced Prostate Cancer

Author： Evans Hannah C.   Wagstaff Antona J.  

Publisher： Adis International

ISSN： 1175-6357

Source： American Journal of Cancer, Vol.3, Iss.3, 2004-01, pp. : 197-201

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Subcutaneous Depot Leuprorelin: A Viewpoint by Navjeet Gandhok and Oliver Sartor

By Gandhok Navjeet   Sartor Oliver  

American Journal of Cancer, Vol. 3, Iss. 3, 2004-01 ,pp. : 203-203

Adis International

Access to resources Recommend Favorite

Leuprolide Acetate: Once-Yearly Subcutaneous Implant in Advanced Prostate Cancer

By Croom K.F.   Perry C.M.  

American Journal of Cancer, Vol. 2, Iss. 1, 2003-01 ,pp. : 57-64

Adis International

Access to resources Recommend Favorite

The UCSF advanced prostate cancer program

By Small E.J.   Harris K.A.   Frohlich M.W.   Bok R.  

Urologic Oncology: Seminars and Original Investigations, Vol. 6, Iss. 5, 2001-09 ,pp. : 197-201

Elsevier

Access to resources Recommend Favorite

What's new in the treatment of advanced prostate cancer?

By Sternberg C.N.  

European Journal of Cancer, Vol. 39, Iss. 2, 2003-01 ,pp. : 136-146

Elsevier

Access to resources Recommend Favorite

Evolving Strategies of Cytotoxic Chemotherapy for Advanced Prostate Cancer

By Raghavan D.   Koczwara B.   Javle M.  

European Journal of Cancer, Vol. 33, Iss. 4, 1997-04 ,pp. : 566-574

Elsevier

Access to resources Recommend Favorite